One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...

Adults taking the novel once-daily oral pill for plaque psoriasis had significantly higher rates of clear or almost clear ...

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

Don't miss out on Boston-area life science news. Subscribe to the Morning Edition or Afternoon Edition for free. Petri Dish: a new AbbVie deal, layoffs, and CFO departures ...

In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see ...

If consummated, the marriage will also give AbbVie access to Aliada's MODEL platform for delivering large-molecule drugs across the blood-brain barrier (BBB). The Boston biotech said the platform ...

Lotte Biologics announced on the 13th that it has signed a memorandum of understanding (MOU) for collaboration in the ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

Although there is currently no cure for Parkinson's, it is possible for many to have a good quality of life thanks to organizations like PRO.